Overview

CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin

Status:
Unknown status

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

This study evaluates the combination of CBT-1® and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1® on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6.

Phase:

Phase 1

Details

Lead Sponsor:

CBA Research
Sarcoma Alliance for Research through Collaboration

Collaborator:

CBA Research

Treatments:

Doxorubicin
Liposomal doxorubicin